The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To compare the efficacy and safety of clarithromycin alone versus rifabutin alone versus the two drugs in combination for the prevention or delay of Mycobacterium avium Complex (MAC) bacteremia or disseminated MAC disease. To compare other parameters such as survival, toxicity, and quality of life among the three treatment arms. To obtain information on the incidence and clinical grade of targeted gynecologic conditions.
Persons with advanced stages of HIV are considered to be at particular risk for developing disseminated MAC disease. The development of an effective regimen for the prevention of disseminated MAC disease may be of substantial benefit in altering the morbidity and possibly the mortality associated with this disease and its treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Mycobacterium Avium-intracellulare Infection HIV Infections |
Drug: Clarithromycin Drug: Rifabutin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomized, Comparative Study of the Safety and Efficacy of Clarithromycin Versus Rifabutin Versus the Combination of Clarithromycin Plus Rifabutin for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disease in HIV-Infected Patients With CD4 Lymphocyte Counts <= 100 Cells/mm3 |
| Estimated Enrollment: | 1100 |
| Study Completion Date: | June 1996 |
Persons with advanced stages of HIV are considered to be at particular risk for developing disseminated MAC disease. The development of an effective regimen for the prevention of disseminated MAC disease may be of substantial benefit in altering the morbidity and possibly the mortality associated with this disease and its treatment.
Patients are randomized to receive clarithromycin alone, rifabutin alone, or the two drugs in combination daily. Patients are evaluated every 4 weeks for the first 8 weeks and every 8 weeks thereafter for the duration of the study. Patients are followed for 24 months. Per amendment, a pharmacokinetic substudy will be conducted.
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Recommended:
- PCP prophylaxis.
Allowed:
- GM-CSF or G-CSF.
- Erythropoietin.
- Therapies (including antiretrovirals) available through expanded access or treatment IND programs.
- Other non-experimental therapies available by prescription.
- Antihistamines other than those specifically excluded.
Patients must have:
- Evidence or diagnosis of HIV infection or a history of an AIDS-defining condition by CDC criteria.
- CD4 count <= 100 cells/mm3 within 90 days prior to study entry.
- Two baseline blood sample cultures negative for MAC within 30 days of study entry.
- No suspected disseminated MAC disease, in the opinion of the clinician.
NOTE:
- Patients with elevated GGT and/or triglycerides are allowed.
NOTE:
- Patients may co-enroll on ACTG 081/981/181, ACTG 175, ACTG 204, ACTG 193, ACTG 241, or other acceptable protocols.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Known or suspected tuberculous infection or other non-tuberculous mycobacterial infection requiring chemotherapy or chemoprophylaxis (with the exception of isoniazid prophylaxis alone).
NOTE:
- Patients may enroll who successfully completed tuberculosis (TB) treatment and have been off anti-TB drugs for more than 6 months with no symptoms of mycobacterial infection.
- Active TB.
- Known hypersensitivity to study drugs.
- Malabsorption as defined by persistent diarrhea with more than 8 stools per day for > 6 weeks.
Concurrent Medication:
Excluded:
- Frequent (more than once per month), repeated, or continuous treatment courses of quinolones, erythromycin, spiramycin, azithromycin, clarithromycin, or clindamycin.
- Concomitant terfenadine or astemizole.
Prior Medication:
Excluded:
- Prophylaxis with azithromycin, clarithromycin, or rifabutin for more than 4 months.
Contacts and Locations
Hide Study Locations| United States, Alabama | |
| Alabama Therapeutics CRS | |
| Birmingham, Alabama, United States, 35294 | |
| United States, California | |
| UCLA CARE Center CRS | |
| Los Angeles, California, United States, 90095 | |
| Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab. | |
| Oakland, California, United States, 94609 | |
| Ucsf Aids Crs | |
| San Francisco, California, United States | |
| United States, District of Columbia | |
| Howard University Hosp., Div. of Infectious Diseases, ACTU | |
| Washington, District of Columbia, United States, 20059 | |
| United States, Florida | |
| Univ. of Miami AIDS CRS | |
| Miami, Florida, United States, 33136 | |
| United States, Hawaii | |
| Univ. of Hawaii at Manoa, Leahi Hosp. | |
| Honolulu, Hawaii, United States, 96816 | |
| United States, Illinois | |
| Chicago Children's CRS | |
| Chicago, Illinois, United States, 60611 | |
| Northwestern University CRS | |
| Chicago, Illinois, United States, 60611 | |
| Rush Univ. Med. Ctr. ACTG CRS | |
| Chicago, Illinois, United States, 60612 | |
| Cook County Hosp. CORE Ctr. | |
| Chicago, Illinois, United States, 60612 | |
| United States, Indiana | |
| Indiana Univ. School of Medicine, Infectious Disease Research Clinic | |
| Indianapolis, Indiana, United States, 46202 | |
| Methodist Hosp. of Indiana | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Iowa | |
| Univ. of Iowa Healthcare, Div. of Infectious Diseases | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Maryland | |
| Johns Hopkins Adult AIDS CRS | |
| Baltimore, Maryland, United States, 21287 | |
| United States, Massachusetts | |
| Massachusetts General Hospital ACTG CRS | |
| Boston, Massachusetts, United States, 02114 | |
| Beth Israel Deaconess - East Campus A0102 CRS | |
| Boston, Massachusetts, United States, 02215 | |
| Beth Israel Deaconess Med. Ctr., ACTG CRS | |
| Boston, Massachusetts, United States, 02215 | |
| Bmc Actg Crs | |
| Boston, Massachusetts, United States, 02118 | |
| United States, Minnesota | |
| University of Minnesota, ACTU | |
| Minneapolis, Minnesota, United States, 55455 | |
| Hennepin County Med. Ctr., Div. of Infectious Diseases | |
| Minneapolis, Minnesota, United States, 55415 | |
| United States, Missouri | |
| St. Louis ConnectCare, Infectious Diseases Clinic | |
| St Louis, Missouri, United States | |
| Washington U CRS | |
| St. Louis, Missouri, United States | |
| United States, Nebraska | |
| Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr. | |
| Omaha, Nebraska, United States, 68198 | |
| United States, New York | |
| Bronx-Lebanon Hosp. IMPAACT CRS | |
| Bronx, New York, United States, 10457 | |
| SUNY - Buffalo, Erie County Medical Ctr. | |
| Buffalo, New York, United States, 14215 | |
| Memorial Sloan-Kettering Cancer Ctr. | |
| New York, New York, United States, 10021 | |
| NY Univ. HIV/AIDS CRS | |
| New York, New York, United States, 10016 | |
| Beth Israel Med. Ctr. (Mt. Sinai) | |
| New York, New York, United States, 10029 | |
| Cornell University A2201 | |
| New York, New York, United States | |
| Univ. of Rochester ACTG CRS | |
| Rochester, New York, United States, 14642 | |
| United States, North Carolina | |
| Unc Aids Crs | |
| Chapel Hill, North Carolina, United States, 27599 | |
| Carolinas HealthCare System, Carolinas Med. Ctr. | |
| Charlotte, North Carolina, United States, 28203 | |
| Regional Center for Infectious Disease, Wendover Medical Center CRS | |
| Greensboro, North Carolina, United States, 27401 | |
| United States, Ohio | |
| Univ. of Cincinnati CRS | |
| Cincinnati, Ohio, United States, 45267 | |
| Case CRS | |
| Cleveland, Ohio, United States, 44106 | |
| MetroHealth CRS | |
| Cleveland, Ohio, United States, 44109 | |
| The Ohio State Univ. AIDS CRS | |
| Columbus, Ohio, United States, 43210 | |
| United States, Pennsylvania | |
| Hosp. of the Univ. of Pennsylvania CRS | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| The Children's Hosp. of Philadelphia IMPAACT CRS | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Washington | |
| University of Washington AIDS CRS | |
| Seattle, Washington, United States, 98122 | |
| Tanzania | |
| Mbeya Med. Research Program, Mbeya Referral Hosp. CRS | |
| Mbeya, Tanzania | |
| Study Chair: | Benson CA | |
| Study Chair: | Cohn DL |
More Information
Additional Information:
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00001030 History of Changes |
| Other Study ID Numbers: | ACTG 196, CPCRA 009, 11172 |
| Study First Received: | November 2, 1999 |
| Last Updated: | March 30, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Rifabutin Mycobacterium avium-intracellulare Infection Acquired Immunodeficiency Syndrome Clarithromycin |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Mycobacterium Infections Mycobacterium avium-intracellulare Infection Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Actinomycetales Infections |
Gram-Positive Bacterial Infections Bacterial Infections Mycobacterium Infections, Atypical Clarithromycin Rifabutin Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Antibiotics, Antitubercular Antitubercular Agents |
ClinicalTrials.gov processed this record on May 19, 2013